Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
10B-15B sounds wonderful but we will be picked up way before that. What I've seen are buyouts when P3 data is indisputable and before IND filing. What I expect to happen here is once we get EMA approval, the BO will happen within several months. Hopefully we are at least $25/sh by then and we fetch at least $3B
Like you said, DOC is accumulating and it is most likely in anticipation of BO.
Invest- I can't agree more although I expect it could happen early 2018 if the EMA approves AXAL. I expect buyout on heels of approval.
On another note, the XBI is on fire, up 3%.
Doesn't it feel like we are going to have a run to 6.13 at the close?
It appears everyone is waiting on partnership news for the anticipated EMA approval. Everything else seems to be ho-hum and has a negative effect on share price.
My guess shorts are making final preps to cover. Available shares are growing, loan rate decreasing and hopefully we hit bottom. I wouldn't be surprised to see us close green in the 8.30's.
Can someone pin Sugarshaker's post? It would be a good reference. Thank you.
Would be nice to break $1. My guess, we will trade between .80 and .90 on less than 15m shares. It's time for s breather.
Wow, only 8 months from end of enrollment in PartA to end of enrollment in PartB.
They expect readout in early 2018 with full readout late 2018. They have SPA and FT designation.
We need to get moving. What is our holdup?
Notice the time the circuit hit? It happen at yesterday's low when we hit 0.75.
Also, the borrowed rate increased over the last two days. It's now at 21.75%.
How long did Lisak perform the test? I'm thinking 12 weeks or less since the human trial is for 12 weeks.
Did Missling state that Biogen is performing another round of testing? I recall hearing that from somewhere.
7th. Do you know how long was that study?
I would still like to know what the plans were for the 10m preferred.
Also, wasn't Biogen going to do another round of testing? Or was that speculation? I'm getting too old to remember.
I agree, Biogen still in play. Let's see if Biogen is mentioned verbally by Missling at the Jeffries conference or maybe Biogen is just listed on a slide as in the last public update.
James,
My comment wasn't meant to be "somewhat negative".
I was just pointing out that in the event BMY was to acquirer us, those 3 former BMY ee's would must likely be happy since their service time would be bridged and that could be very profitable in respect to their pension. Though those 3 have a connection to BMY, I don't see BMY having any inside leverage. To me it's just a coincidence. Nothing more, nothing less. My sight is on EMA approval and partnership.
I'm looking for it but no dates are given. I know I read it somewhere that Rett was for 2H of 2017. Interesting in 10Q when talking about current AD trial it states " The trial is independent of the company's PLANNED larger P2/3 double-blind, placebo-controlled study. Why use the word "planned"? It sounds like it's not currently being worked on. Why not use the word "upcoming" or add its in the works. We know it is.
For Rett it says "in 2017". So it looks like 1H was removed.
No year given for PD.
They intend to identify and initiate discussions with potential partners within next 13 months. It says that in every 10Q.
All this is listed on page 3 under "Our Current Business" section. Page 3 follows page F-14.
I believe the patent covers A2-73 plus "whatever". I don't think it is only for AD. I'm. It certain, thus my question.
It would be great if they all happen however I believe some of the dates have changed since last reporting.
I bet all 3 would like their services years bridged if BMY is an actual suitor.
Right now, we should just focus on the pending distribution news for Europe. That is most likely the major item that will propel us back up to 20+.
And I bet it's below 8.5m today.
Bourbon,
If true that BMY needs this so badly, why isnt BMY paying for it all?
Maybe, just maybe DOC enticed BMY to go for it now (by offering to pay for it) just to add some fireworks with his discussions with others. Bidding war perhaps? More the merrier.
Power, you said:
So, how long does it take to prepare patent documents, drawings, etc. for four new drug patents?
Would there be a new patent if we already have the patent plus?
K9, you stated:
"Everytime Missling puts out some PR and the price jumps the short cabal puts out a blast of hit articles driving the price back down."
I'm starting to believe that Missling is going to leave the "pumping" to others (like Maxim, Noble and soon to be Jeffries). Do you recall a hit piece after Noble's recommendation? I think there was one and it had zero impact. Just wait and see what Jeffries rec will do. I bet we hear of the patent plus before presentation. Subsequently (the following week or two) Jeffries will issue a buy recommendation and we jump to double digits. Wouldn't be surprised to see a jump up to 8-9 before their rec. this will allow their privileged account holders ample time to buy before the glowing recommendation. The Rett trial will be announced shortly thereafter (early July, let's say Monday 7/11).
Perhaps Missling will use the Jeffries conference to announce the plus patent and Jeffries will use that to project price target.
With Missling's background he seems more comfortable in these venues than updating shareholders. It seems like he wants the Maxims, Nobles and Jefferies of the world to do that part for him. I'm not criticizing just stating on what it appears.
Was the spike last week due to today's news with BMS? Hmmmmm!!!!
I don't think it will fun pass $2. More like 1.20 to 1.50. You need to save some room for buyout. Buyout won't be more than 4.50 to 6. IMHO.
The FDA fee is sizable I believe. Is the PI and facilities sizable?
.92 appears to have resistance waiting.
Go back a year and look at the chart for CPXX. The same will happen here.
He has something positive to say in the patent. For some reason he is holding that back. Why??????
Too busy to review with attorney (possibly, remember this is a one man show) or holding for maximum effect (my guess not) or under NDA (no reason to hold up PR for that) or something else. There is really no excuse to hold up unless they are questioning something which doesn't seem to be the case.
While all this bickering is going on, the shorts are covering big time.
I had a significant number of my loan shares returned to me today.
My guess is we will hear news before flag day.
We had a nice run for three days. I think we settle in the .75 - .95 range for a while. Ultimately we will most likely get bought out between $4 and $6 but that's months away. Enjoy the run. It will continue at some point.
We will get our first genuine multi dollar pop when we see a PR that the first patient in the Rett trial was treated.
It's a non event. There is only a couple folks who thought we would experience a significant drop. We may but it won't be due to LPC.
Perhaps this is a case where we went to BMS and asked them to try.
Doc: give it a try. We will cover our part and pay third party costs. All you have to do is just incorporate the study within your other studies. It should be minimal expense to you. You have everything you need.
BMS: oh what the hell. Just to confirm, you are picking up third party expenses?
DOC: yes, we did major dilution 9 months ago so we are flush with cash. Deal?
BMS: deal!
DOC: (too himself)....maybe this will get share price to drop so I can pick up s few more shares and then later this year...BAM, POP, POW...just like Batman...I PR the AXAL news.
I don't think funding is an issue to cause delay. It's basically a one man show so I suspect Missling is busy juggling other things (Rett, upcoming events,etc).
Premarket awlfully quiet with the LPC deal. No tutes seem to care.
Where is the patent news? It's weeks overdue.
Stop you??? The problem is, it seems like we are the only few who believes and can comprehend what we have. With the depth of expertise on our board, I'm just baffled why more folks in the scientific community don't know about us. This is just another example of the "tip of the iceberg" comment. One day everybody is going to wake up at the same time and have an "ah-ha" moment. This will most likely occur once the 12 week data is released on the Rett trial (unless there are early milestones to be shared).
Hey Tom, with all due respect, I feel your point of view is always biased to the negative side. I don't think Friday's news is negative nor do I believe it is a surprise. I will be shocked if we close down more than $0.10. I actually believe, now that the anticipated issuance of shares are known we will be up this next week. Most (if not all investors knew this was coming, especially in the light of the preferred shares getting voted down). The stage is now set for the flow of great news starting with the patent plus approval. I was wondering why the patent news wasn't released. I bet it was "held" up for cursory review by outside counsel.to allow time for the PR on the 5m to be issued. Just my take.
Personally, I believe the trend is up. I expect we will continue to have swings (up. 15%, down 5%). It would be nice to play the swings but anything can happen at his point. I believe we will get bought out within the next 12 months between $5 and $6 per share.
Let's hope. Good luck to everyone.
And Fadiran will help with the first 3 items:
holding meetings with the sponsor and the review team throughout the development of the drug
providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable
taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients exposed to a potentially less efficacious treatment
From another company. Wouldn't it be nice to hear this here
______is under confidentiality agreements with a number of companies for a commercial partnership for the marketing of aldoxorubicin. The Company believes those active discussions may be further advanced by this latest news.